Q1: what
percentage of the company is 40% of RA? Or does that even matter when
the number of unissued authorized shares is so large compared to
authorized shares?
On a standalone basis RA is 100% for now. Shares unisued is always in the backdrop but not critical at this point as some see them as a opening for unwarranted future dilution but to some they are seen as a hindrance to a hostile takeover. As bio guru indicated the basic tilmanocept imaging science is regulatory approved and safety validated with big potential, but the normalized equity value graph shows the upside even for RA is not yet priced in to the shares/equity value, so significant potential upside in share price exists.
Q2:
Since the coming dilution, whatever form it takes, could be seen coming
for a long time, has the market priced that in to the current pps? ie
if current pps is $1.50 is it possible to raise $8mm by selling 5.33mm
shares @ 1.50?. That would mean the market cap would be going up
dollar-for-dollar by the amount raised. In my anxiety I was figuring
the market cap would remain the same after dilution so by increasing
issued shares from about 18mm to about 23mm $1.50 becomes $1.17
Recently the dilution has been a positive as bio guru noted as informed investors were willing to take at a 0 discount which is very telling and price reacted positively from that event. How will the price respond to the next dilution is not predictable until one knows the factoids, but if it is tied to good trial news, the discount is low and/or it is structured without a future dilution handle like many of the historic financing deals under Neoprobe and early teens Naivdea, then it could stabilize or add to share price